Unicycive Therapeutics Q4 EPS $(0.82) Misses $0.03 Estimate

Unicycive Therapeutics (NASDAQ: UNCY) reported a Q4 loss of $(0.82) per share, missing the analyst consensus estimate by $0.03. This represents a 68.46% improvement compared to a loss of $(2.60) per share in the same quarter last year.